NCT07707219

Brief Summary

Visual impairment, whether central or peripheral, may influence the plasticity of other sensory modalities, such as taste and smell. Taste-evoked potentials (TEPs) and smell-evoked potentials (SEPs)-methods for analyzing brain activity in response to taste and smell stimuli-allow for the objective assessment of these interactions. This approach has already demonstrated its value in the study of cognitive disorders. This study aims to demonstrate an enhancement of taste and smell capabilities that could compensate for specific visual impairments, particularly in situations involving food choices.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Timeline
24mo left

Started Sep 2026

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 2, 2026

Completed
14 days until next milestone

First Posted

Study publicly available on registry

July 16, 2026

Completed
2 months until next milestone

Study Start

First participant enrolled

September 1, 2026

Expected
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2028

Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2028

Last Updated

July 16, 2026

Status Verified

July 1, 2026

Enrollment Period

2 years

First QC Date

July 2, 2026

Last Update Submit

July 15, 2026

Conditions

Outcome Measures

Primary Outcomes (2)

  • Average latency of PEG (Taste-Evoked Potentials) peaks

    Measurement of the mean latency of taste-evoked potential peaks in visually impaired patients versus control subjects following purely gustatory stimulation (sucrose).

    At the baseline

  • Average amplitude of PEG (Taste-Evoked Potentials) peaks

    Measurement of the mean amplitude of taste-evoked potential peaks in visually impaired patients versus control subjects following purely gustatory stimulation (sucrose).

    At the baseline

Study Arms (2)

Patients with retinal dystrophy and central or peripheral visual field defects

OTHER
Other: Taste and smell evaluationOther: Recording of evoked potentials (EP)

Healthy volunteers

OTHER
Other: Taste and smell evaluationOther: Recording of evoked potentials (EP)

Interventions

Determination of taste and smell ability scores using standardized methods (ETOC and Taste Strips)

Healthy volunteersPatients with retinal dystrophy and central or peripheral visual field defects

A recording of gustatory evoked potentials (GEP) and olfactory evoked potentials (OEP) in response to stimuli consisting of sucrose solution, vanillin, and a combination of the two.

Healthy volunteersPatients with retinal dystrophy and central or peripheral visual field defects

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Adult: ≥ 18 years and ≤ 60 years
  • Individual who has given oral consent
  • Individual who has been fasting (no food, drink, or tobacco) for at least 1 hour prior to PEG and PEO measurement
  • No cognitive complaints and normal neurological examination.
  • Group of patients with visual impairment:
  • A. Central: documented bilateral macular dystrophy (e.g., Stargardt disease, Best disease) with confirmed central scotoma (CV 24.2, 10.2, or 30.2).
  • B. Peripheral: documented bilateral peripheral retinal dystrophy with confirmed peripheral involvement (CV 30-2 or 24-2).
  • Control group: a person with normal vision and no known ophthalmological abnormalities (normal visual acuity and fundus examination) who is precisely matched by sex and smoking status (former smoker who has quit vs. nonsmoker), and approximately matched by age (± 5 years) to a visually impaired participant included in the study.

You may not qualify if:

  • For this group: patients with visual impairments:
  • Individuals who are not enrolled in or eligible for a social security program
  • Individuals subject to a legal protective measure (guardianship, conservatorship)
  • Individuals subject to judicial safeguard measures
  • Adults who are legally incapacitated or unable to give informed consent
  • Documented COVID-19 infection within the 6 months prior to enrollment
  • Active smokers (≥1 cigarette per day) or users of any other inhaled substances (water pipe, cannabis, etc.)
  • Participants following a sugar-free diet
  • Participants with diabetes, of any type
  • Participants taking medication (ongoing during the study) that interferes with taste perception • Pregnant or breastfeeding women
  • Individuals with neurodegenerative diseases (Parkinson's, Alzheimer's)
  • Individuals with braids, dreadlocks, or any other hairstyle that prevents electrodes from being placed in sufficiently precise locations on the scalp.
  • Overweight subjects with a BMI ≥ 35 kg/m²

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Chu Dijon Bourgogne

Dijon, 21000, France

Location

MeSH Terms

Conditions

Blindness, Cortical

Interventions

Taste

Condition Hierarchy (Ancestors)

BlindnessVision DisordersSensation DisordersNeurologic ManifestationsNervous System DiseasesEye DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

SensationNervous System Physiological PhenomenaMusculoskeletal and Neural Physiological Phenomena

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 2, 2026

First Posted

July 16, 2026

Study Start (Estimated)

September 1, 2026

Primary Completion (Estimated)

September 1, 2028

Study Completion (Estimated)

September 1, 2028

Last Updated

July 16, 2026

Record last verified: 2026-07

Locations